ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
1. REGEN-007 results show significant kidney function improvement in Group 1. 2. 78% reduction in eGFR decline was statistically significant (p<0.001). 3. Safety profile of rilparencel remains consistent with previous studies. 4. FDA Type B meeting planned to confirm eGFR slope as a surrogate endpoint. 5. ProKidney targets accelerated approval for rilparencel to address CKD market.